STOCK TITAN

Tandem Diabetes (NASDAQ: TNDM) EVP issued 2,827 shares, 809 withheld

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by executive officer Susan Morrison, EVP & Chief Admin. Officer. On 2026-08-15, 2,827 shares of common stock were acquired through the vesting and conversion of restricted stock units, while 809 shares were withheld by the issuer to satisfy tax withholding obligations at $22.72 per share. Footnotes state that no shares were sold in the market; the transactions reflect equity compensation vesting and related tax withholding rather than open-market trading.

Positive

  • None.

Negative

  • None.
Insider Morrison Susan
Role EVP & Chief Admin. Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit F2, F3, F4 1,097 $0.00 $0.00
Exercise Restricted Stock Unit F5, F3, F6 1,730 $0.00 $0.00
Exercise Common Stock 1,097 $0.00 $0.00
Tax Withholding Common Stock F1 314 $22.72 $7K
Exercise Common Stock 1,730 $0.00 $0.00
Tax Withholding Common Stock F1 495 $22.72 $11K
Holdings After Transaction: Restricted Stock Unit — 15,405 shares (Direct); Common Stock — 52,788 shares (Direct)
Footnotes (6)
  1. F1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
  2. F2. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
  3. F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
  4. F4. One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
  5. F5. Awarded on May 30, 2025 pursuant to the 2023 Plan.
  6. F6. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
RSUs Converted to Common Stock (2024 grant leg) 1,097 shares Restricted Stock Units converting into common stock on 2026-08-15 from the May 23, 2024 award
RSUs Converted to Common Stock (2025 grant leg) 1,730 shares Restricted Stock Units converting into common stock on 2026-08-15 from the May 30, 2025 award
Shares Withheld for Taxes (first leg) 314 shares Common shares withheld to satisfy tax withholding requirements at $22.72 per share
Shares Withheld for Taxes (second leg) 495 shares Additional common shares withheld to satisfy tax withholding requirements at $22.72 per share
Tax Withholding Price $22.72 per share Per-share value applied to Form 4 transactions coded F for tax withholding
Total RSU Exercises 2,827 shares Aggregate derivative exercises (code M) reported in the transaction summary
Shares Withheld for Tax or Exercise Price 809 shares Total shares in code F transactions used for payment of tax liability
Restricted Stock Unit financial
"security_title "Restricted Stock Unit" with each RSU representing a contingent right to receive stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"Each RSU represents a contingent right to receive either one share of common stock"
tax withholding requirements financial
"Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of RSUs"
2023 Long-Term Incentive Plan financial
"Awarded pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"

FAQ

What insider equity transactions did TNDM report for Susan Morrison on August 15, 2026?

On 2026-08-15, Susan Morrison had 2,827 shares of TANDEM DIABETES CARE INC common stock issued from RSU vesting, with 809 shares withheld by the issuer to cover tax obligations related to the vesting.

Did Susan Morrison sell any TNDM shares in the August 15, 2026 Form 4?

No market sales occurred; 809 shares were withheld by TANDEM DIABETES CARE INC to satisfy tax withholding requirements upon RSU vesting, and the filing’s footnote explicitly states that no shares were sold in the market.

How many TNDM shares vested from Susan Morrison’s restricted stock units on August 15, 2026?

A total of 2,827 shares of TANDEM DIABETES CARE INC common stock were issued upon the exercise or conversion of vested restricted stock units, split across awards granted in 2024 and 2025 under the company’s 2023 Long-Term Incentive Plan.

What price was used for tax withholding on Susan Morrison’s TNDM shares?

For tax withholding, TANDEM DIABETES CARE INC used a price of $22.72 per share on 809 withheld shares, as shown in the Form 4 transactions coded “F” for payment of tax liability by delivering or withholding securities.

Which equity plan governed Susan Morrison’s RSU awards reported by TNDM?

The RSUs were granted under TANDEM DIABETES CARE INC’s 2023 Long-Term Incentive Plan. Awards were made on May 23, 2024 and May 30, 2025, with one-third vesting on specific dates and remaining units vesting in eight equal quarterly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morrison Susan

(Last)(First)(Middle)
12400 HIGH BLUFF DRIVE

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Admin. Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/15/2026M1,097A$051,867D
Common Stock08/15/2026F(1)314D$22.7251,553D
Common Stock08/15/2026M1,730A$053,283D
Common Stock08/15/2026F(1)495D$22.7252,788D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)(3)08/15/2026M1,097 (4) (4)Common Stock1,097$03,290D
Restricted Stock Unit(5)(3)08/15/2026M1,730 (6) (6)Common Stock1,730$012,115D
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
2. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
5. Awarded on May 30, 2025 pursuant to the 2023 Plan.
6. One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Remarks:
/s/ Jerilyn Laskie, Attorney-in-Fact for Susan M. Morrison08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)